Monday, December 11, 2017 11:32:56 AM
5:25 AM ET 12/11/17 | Briefing.com
Co announced data supporting its non-viral approach to rapid manufacture of chimeric antigen receptor (CAR)-modified T cells to treat patients with cancers Two trials demonstrated that first-generation SB-modified CD19-specific CAR+ T cells appear to provide long-term cancer control when infused after hematopoietic stem-cell transplantation (HSCT) for patients with advanced CD19+ malignancies and could be detected years after administration in some recipients. All seven patients with advanced CD19+ non-Hodgkin's lymphoma (NHL) that received autologous T cells were alive at a median survival of 40 months since infusion, with progression-free survival (PFS) reported at 86% and overall survival (OS) at 100%. For 19 patients with advanced CD19+ acute lymphoblastic leukemia (ALL) and NHL infused with allogeneic T cells following HSCT, nine patients were alive with a median survival of 31 months. The PFS rate and OS rates are 32% and 49%, respectively. Of the subset of eight patients who received donor-derived T cells after haploidentical HSCT, PFS and OS rates are 50% and 63%, respectively. Persistence of circulating SB-modified CAR+ T cells was demonstrated at two years in an autologous and allogeneic patient and for four years in two autologous patients.
Recent PGEN News
- Precigen to Participate in the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:00:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:25:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:19:00 PM
- Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates • PR Newswire (US) • 08/14/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 09:09:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:04:35 PM
- Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th • PR Newswire (US) • 08/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:19:45 PM
- Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock • PR Newswire (US) • 08/08/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 08:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Precigen Announces Proposed $30 Million Public Offering of Common Stock • PR Newswire (US) • 08/06/2024 08:04:00 PM
- Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:21:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:20:43 PM
- Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch • PR Newswire (US) • 07/23/2024 12:01:00 PM
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response • PR Newswire (US) • 06/03/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:03:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:45 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/28/2024 08:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:44:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM